Skip to Main Content

Could a blood test help more lung cancer patients get drugs that are targeted to the genetic weaknesses of their tumors?

Yes, according to summary results of a 282-patient clinical trial being made available Wednesday. The result is a boon for Guardant Health, the San Francisco-based startup that sells the test, Guardant360, which is a “liquid biopsy” that works by detecting fragments of DNA in the bloodstream. The full study will be presented in full at the annual meeting of the American Association for Cancer Research in early April.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!